Actinium Pharmaceuticals
(NYSE: $ATNM) to Sponsor and Participate in Be The Match® Walk+Run to Raise
Awareness for Bone Marrow Transplant
NEW
YORK - September 26, 2016 (Investorideas.com Newswire) Actinium
Pharmaceuticals, Inc. (NYSE: ATNM)
("Actinium" or "the Company"), a biopharmaceutical Company
developing innovative targeted payload immunotherapeutics for the treatment of
advanced cancers, announced today that the Company has sponsored and will
participate in the upcoming Be The Match® Walk+Run being held on Saturday,
October 1, 2016, at Firefighter's Field on Roosevelt Island, New York, New
York. The goal of the Walk+Run is to raise awareness for bone marrow transplant
(BMT), raise funds to help transplant patients, support marrow transplant
research and add more potential marrow donors to the Be The Match Registry®.
Employees
of Actinium Pharmaceuticals, together with their family and friends, will be
participating in the Be The Match® Walk+Run to raise awareness and funds. To
support Team Actinium and Be The Match® , please visit Actinium's team page
here: Click here to view the team page for Team Actinium
"Actinium
is focused on developing products which may improve the lives of patients with
leukemia, lymphoma or one of the many other life-threatening diseases that
could benefit from a bone marrow transplant," stated David Gould, M.D.,
Actinium's Senior Vice President of Corporate Development and Corporate
Affairs. "Be The Match provides incredible support to these patients and
we are honored to have the ability to sponsor such a worthwhile event and we
are excited to participate in the Walk+Run on October first."
About Be The Match®
For
people with life-threatening blood cancers—like leukemia and lymphoma—or other
diseases, a cure exists. Be The Match connects patients with their donor match
for a life-saving marrow or umbilical cord blood transplant. People can
contribute to the cure as a member of the Be The Match Registry, financial
contributor or volunteer. Be The Match provides patients and their families
one-on-one support, education, and guidance before, during and after
transplant.
Be
The Match is operated by the National Marrow Donor Program® (NMDP), a nonprofit
organization that matches patients with donors, educates health care
professionals and conducts research so more lives can be saved. To learn more
about the cure, visit BeTheMatch.org or call 1 (800) MARROW-2
Read this release
in full at http://www.investorideas.com/CO/ATNM/news/2016/09261BoneMarrowTransplant.asp
About Actinium Pharmaceuticals
Actinium
Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based biopharmaceutical
company developing innovative targeted payload immunotherapeutics for the
treatment of advanced cancers. Actinium's targeted radioimmunotherapy products
are based on its proprietary delivery platform for the therapeutic utilization
of alpha-emitting Actinium-225 and Bismuth-213 and certain beta emitting
radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's
lead radiopharmaceutical product candidate Iomab-B is designed to be used, upon
approval, in preparing patients for hematopoietic stem cell transplant,
commonly referred to as bone marrow transplant. The Company is conducting a
single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory or
relapsed AML patients over the age of 55 with a primary endpoint of durable
complete remission. The Company's second product candidate, Actimab-A, is
continuing its clinical development in a Phase 1/2 trial for patients newly
diagnosed with AML over the age of 60 in a single-arm multicenter trial.
Forward-Looking
Statements for Actinium Pharmaceuticals, Inc.
This
news release contains "forward-looking statements" as defined in the
Private Securities Litigation Reform Act of 1995. These statements are based on
management's current expectations and involve risks and uncertainties, which
may cause actual results to differ materially from those set forth in the
statements. The forward-looking statements may include statements regarding
product development, product potential, or financial performance. No
forward-looking statement can be guaranteed and actual results may differ
materially from those projected. Actinium Pharmaceuticals undertakes no
obligation to publicly update any forward-looking statement, whether as a
result of new information, future events, or otherwise.
Contact:
Steve
O'Loughlin
Vice President, Finance and Corporate Development
Actinium Pharmaceuticals, Inc.
soloughlin@actiniumpharma.com
Vice President, Finance and Corporate Development
Actinium Pharmaceuticals, Inc.
soloughlin@actiniumpharma.com
Be the Match Foundation®
Melissa Neill
Strategic Public Relations Specialist
763-406-8762
Melissa Neill
Strategic Public Relations Specialist
763-406-8762
Source:
Actinium Pharmaceuticals
This news is
published on the Investorideas.com Newswire - a global digital news source for
investors and business leaders
Sign up for free news alerts
Disclaimer/Disclosure:
Investorideas.com is a digital publisher of third party sourced news, articles
and equity research as well as creates original content, including video,
interviews and articles. Original content created by investorideas is protected
by copyright laws other than syndication rights. Our site does not make
recommendations for purchases or sale of stocks, services or products. Nothing
on our sites should be construed as an offer or solicitation to buy or sell
products or securities. All investment involves risk and possible loss of
investment. This site is currently compensated for news publication and
distribution, social media and marketing, content creation and more. Contact
each company directly regarding content and press release questions. Disclosure
is posted for each compensated news release, content published /created if
required but otherwise the news was not compensated for and was published for
the sole interest of our readers and followers. More disclaimer info:http://www.investorideas.com/About/Disclaimer.asp.
Disclosure:
One month news , social media and marketing Actinium Pharmaceuticals, Inc.
(ATNM) by third party IRTH Communications starting September 19, 2016: three
thousand per month.
No comments:
Post a Comment